Technology | November 21, 2013

Civco Advances Real-Time Planning for Brachytherapy With EX3 Stepper

brachytherapy systems prostate technology treatment planning civco ex3 stepper
November 21, 2013 — Civco Medical Solutions announced that its EX3 Stepper for low-dose rate (LDR) and high-dose rate (HDR) ultrasound-guided brachytherapy for prostate cancer detection and treatment received U.S. Food and Drug Administration (FDA) 510(k) clearance.
  
The EX3 Stepper’s modular design reports angular and linear position directly to the manufacturer’s treatment planning software intraoperatively. Through direct communication, the stepper offers rapid connection for data analysis and reduces clutter in the surgical suite. The unique design of the EX3 also features a removable electronic unit that mitigates the risk of damaging transmission components and reduces cleaning time after the procedure.
 
Civco’s EX3 Stepper, like its predecessor the EXII, offers compatibility for BK Medical, GE Healthcare, Hitachi Aloka and Siemens transrectal ultrasound probes, and it is currently validated for use with Varian Vitesse and VariSeed treatment planning software.
 
The EX3 has also received the CE mark the EX3 for sale in the European Union and other countries that recognize the CE mark.
 
For more information: www.civco.com

Related Content

Insightec Announces Expanded Reach of MR-Guided Focused Ultrasound
News | Focused Ultrasound Therapy | August 22, 2017
Insightec announced recently that worldwide adoption of magnetic resonance (MR)-guided focused ultrasound continues to...
UCLA Study Offers Roadmap to Personalized Therapies for Sarcoma
News | Oncology Diagnostics | August 22, 2017
A new UCLA study is the first to identify patient and tumor characteristics that predict the successful creation of...
Sponsored Content | Videos | Information Technology | August 22, 2017
Melissa Martin, MS, president of the American Association of Physicists in Medicine (AAPM), discusses her vision of t
Sponsored Content | Videos | Proton Therapy | August 21, 2017
Mark Pankuch, Ph.D., director of medical physics at the Northwestern Medicine Chicago Proton Center, discusses the cl
Summit Cancer Center-Boise Treats First Cancer Patients With Accuray Radixact System
News | Image Guided Radiation Therapy (IGRT) | August 21, 2017
Accuray Inc. and the Summit Cancer Center-Boise announced that the center is now treating patients with the Radixact...
MedStar Georgetown Proton Center Selects RayStation for Treatment Planning
News | Treatment Planning | August 17, 2017
August 17, 2017 — The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
DOSIsoft Releases ISOgray Proton Therapy Treatment Planning System
Technology | Treatment Planning | August 15, 2017
DOSIsoft SA announced the official release, with CE marking, of ISOgray Treatment Planning System (TPS) release 4.3 for...
First Radixact Results Presented at AAPM 2017
News | Radiation Therapy | August 10, 2017
Accuray Inc. announced that the first studies validating the benefits of the Radixact System were presented at the 59th...
Overlay Init